Analystreport

Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was upgraded by analysts at B. Riley from a "neutral" rating to a "buy" rating. They now have a $128.00 price target on the stock.

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com